200 related articles for article (PubMed ID: 28762373)
1. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.
Calio B; Sidana A; Sugano D; Gaur S; Jain A; Maruf M; Xu S; Yan P; Kruecker J; Merino M; Choyke P; Turkbey B; Wood B; Pinto P
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):436-441. PubMed ID: 28762373
[TBL] [Abstract][Full Text] [Related]
2. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.
Sidana A; Watson MJ; George AK; Rastinehad AR; Vourganti S; Rais-Bahrami S; Muthigi A; Maruf M; Gordetsky JB; Nix JW; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2018 Jul; 36(7):341.e1-341.e7. PubMed ID: 29753548
[TBL] [Abstract][Full Text] [Related]
3. Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Muthigi A; Sidana A; George AK; Kongnyuy M; Shakir N; Kadakia M; Maruf M; Frye TP; Mertan F; Su D; Merino MJ; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2016 Sep; 48(9):1445-52. PubMed ID: 27305918
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Cancer Detection Rates Between Template Systematic Biopsies Obtained Using Magnetic Resonance Imaging-Ultrasound Fusion Machine and Freehand Transrectal Ultrasound-Guided Systematic Biopsies.
Hoge C; Maynor S; Guan T; Naffouje R; Rao M; Verma S; Sidana A
J Endourol; 2020 Oct; 34(10):1095-1098. PubMed ID: 32631097
[No Abstract] [Full Text] [Related]
5. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy.
Maruf M; Fascelli M; George AK; Siddiqui MM; Kongnyuy M; DiBianco JM; Muthigi A; Valayil S; Sidana A; Frye TP; Kilchevsky A; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):179-185. PubMed ID: 28220802
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men.
Kongnyuy M; Siddiqui MM; George AK; Muthigi A; Sidana A; Maruf M; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):348-351. PubMed ID: 28440325
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
8. Patient Experience of Systematic Versus Fusion Prostate Biopsies.
Eineluoto JT; Järvinen P; Kilpeläinen T; Lahdensuo K; Kalalahti I; Sandeman K; Mirtti T; Rannikko A
Eur Urol Oncol; 2018 Aug; 1(3):202-207. PubMed ID: 31102622
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
10. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
11. Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.
Sugano D; Sidana A; Jain AL; Calio B; Gaur S; Maruf M; Merino M; Choyke P; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2020 Apr; 52(4):633-638. PubMed ID: 31807974
[TBL] [Abstract][Full Text] [Related]
12. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
[TBL] [Abstract][Full Text] [Related]
13. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
Mannaerts CK; Engelbrecht MRW; Postema AW; van Kollenburg RAA; Hoeks CMA; Savci-Heijink CD; Van Sloun RJG; Wildeboer RR; De Reijke TM; Mischi M; Wijkstra H
BJU Int; 2020 Oct; 126(4):481-493. PubMed ID: 32315112
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI-ultrasound fusion prostate biopsy in patients without prior diagnosis of prostate cancer: beyond centers of excellence.
Verma S; Zegar J; Hoge C; McGready J; Sidana A
Aging Male; 2020 Dec; 23(5):1570-1575. PubMed ID: 33446002
[TBL] [Abstract][Full Text] [Related]
15. mpMRI-targeted biopsy of the prostate in men ≥ 75 years. 7-year report from a high-volume referral center.
Chaloupka M; Pyrgidis N; Ebner B; Pfitzinger PL; Volz Y; Berg E; Enzinger B; Atzler M; Ivanova T; Pfitzinger PL; Stief CG; Apfelbeck M; Clevert DA
Clin Hemorheol Microcirc; 2024; 86(1-2):63-70. PubMed ID: 37718788
[TBL] [Abstract][Full Text] [Related]
16. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract][Full Text] [Related]
17. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
[TBL] [Abstract][Full Text] [Related]
18. How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?
Herlemann A; Overland MR; Washington SL; Cowan JE; Westphalen AC; Carroll PR; Nguyen HG; Shinohara K; Cooperberg MR
Eur Urol Focus; 2021 Nov; 7(6):1268-1273. PubMed ID: 32868222
[TBL] [Abstract][Full Text] [Related]
19. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
[TBL] [Abstract][Full Text] [Related]
20. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
